Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk

Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk

Munich, Germany, 16 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 26% vs placebo, when added to standard of care in 3,297 adults with type 2 diabetes at high CV risk.1

These results were based on an accumulation of first major adverse CV events (MACE) in 254 people.1

The main results from SUSTAIN 6 were presented today at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 20162 and also published in the New England Journal of Medicine.1

References

  1. Marso SP, Bain S, Consoli A, et al. Semaglutide and cardiovascular outcomes, efficacy and safety in type 2 diabetes. New England Journal of Medicine. 2016; In Press.

16 Sep 2016

Source: http://www.novonordisk.com/

September 19, 2016 / Pharma News